TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials

TG Therapeutics ( TGTX ) announced 4Q 2024 earnings that came with a lot of positive commentary towards the future of Briumvi. Expectations were in range coming into the earnings as the company preannounced $103.6M for 4QAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in TGTX over the next 72 hours. I wrote this ...